

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting

DoubleTree by Hilton Washington DC/Silver Spring
8727 Colesville Road, Silver Spring, Maryland
May 10, 2012

DRAFT MEETING ROSTER

DESIGNATED FEDERAL OFFICER (Non-Voting)

Paul T. Tran, R.Ph

Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Vera A. Bittner, M.D., M.S.P.H.

Professor of Medicine
Section Head, Preventive Cardiology
The University of Alabama at Birmingham
Birmingham, Alabama

Edward W. Gregg, Ph.D.

Chief, Epidemiology and Statistics Branch
Division of Diabetes Translation
Centers for Disease Control and Prevention (CDC)
Atlanta, Georgia

Erica H. Brittain, Ph.D.

Mathematical Statistician
Biostatistics Research Branch
National Institute of Allergy and Infectious Diseases
(NIAID), National Institutes of Health (NIH)
Bethesda, Maryland

Ida J. Spruill, Ph.D., R.N.

(Consumer Representative)
Assistant Professor, College of Nursing
Medical University of South Carolina
Charleston, South Carolina

David M. Capuzzi, M.D., Ph.D.

Professor of Medicine and Biochemistry
Thomas Jefferson University &
Lankenau Institute for Medical Research
Philadelphia, Pennsylvania

Abraham Thomas, M.D., M.P.H., FACP

(Chairperson)
Division Head, Endocrinology, Diabetes, Bone, and
Mineral Disorders
Henry Ford Hospital
Whitehouse Chair of Endocrinology
Detroit, Michigan

Eric I. Felner, M.D., MSCR

Associate Professor of Pediatrics
Division of Pediatric Endocrinology
Director, Pediatric Endocrinology Fellowship Program
Emory University School of Medicine
Atlanta, Georgia

Lamont G. Weide, M.D., Ph.D., FACE

Chief, Diabetes & Endocrinology
Professor, Internal Medicine
University of Missouri - Kansas City
Truman Medical Centers, Diabetes Center
Kansas City, Missouri

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting

DoubleTree by Hilton Washington DC/Silver Spring
8727 Colesville Road, Silver Spring, Maryland
May 10, 2012

DRAFT MEETING ROSTER (cont.)

ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)

Mads F. Rasmussen, M.D., Ph.D.

(Industry Representative)

Executive Director
Diabetes - Clinical Development and Research
Clinical Development, Medical and Regulatory
Affairs, Novo Nordisk Inc.
Princeton, New Jersey

TEMPORARY MEMBERS (Voting)

Daniel H. Bessesen, M.D.

Professor of Medicine
University of Colorado School of Medicine
Chief of Endocrinology
Denver Health Medical Center
Denver, Colorado

Heidi M. Connolly, M.D.

Professor of Medicine
Consultant in Cardiovascular Diseases
Mayo Clinic
Rochester, Minnesota

Katherine M. Flegal, Ph.D.

Senior Research Scientist
Distinguished Consultant
National Center for Health Statistics, CDC
Hyattsville, Maryland

Allison B. Goldfine, M.D.

Assistant Director of Clinical Research
Joslin Diabetes Center, Research Division
Boston, Massachusetts

Peter A. Gross, M.D.

Chair
Hackensack Physician-Hospital Alliance ACO, LLC
Hackensack University Medical Center
Hackensack, New Jersey

Ed J. Hendricks, M.D.

Medical Director
Center for Weight Management
Roseville and Sacramento, California

William R. Hiatt, M.D., FACP

Professor of Medicine, Division of Cardiology
University of Colorado School of Medicine
President, Colorado Prevention Center (CPC) Clinical
Research
Aurora, Colorado

Sanjay Kaul, M.D.

Director, Fellowship Training Program in Cardiovascular
Diseases
Cedars-Sinai Heart Institute
Professor, David Geffen School of Medicine at UCLA
Division of Cardiology
Cedar Sinai Medical Center
Los Angeles, California

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting

DoubleTree by Hilton Washington DC/Silver Spring
8727 Colesville Road, Silver Spring, Maryland
May 10, 2012

DRAFT MEETING ROSTER (cont.)

TEMPORARY MEMBERS (Voting)

David E. Malarkey D.V.M., Ph.D., DACVP

Head, National Toxicology Program Pathology Group
Cellular and Molecular Pathology Branch
National Institute of Environmental Health Sciences
(NIEHS), NIH
Research Triangle Park, North Carolina

Robert J. Smith, M.D.

Professor of Medicine (Endocrinology)
Alpert Medical School of Brown University
East Providence, Rhode Island

Ernest E. McConnell, D.V.M., M.S.

President of Toxpath, Inc.
Veterinary Pathology
Raleigh, North Carolina

Angelica Walden

(Patient Representative)
Hephzibah, Georgia

Lewis S. Nelson, M.D.

Professor of Emergency Medicine
Director, Fellowship in Medical Toxicology
New York University School of Medicine
New York City Poison Control Center
New York, New York

Jack A. Yanovski, M.D., Ph.D.

Chief, Section on Growth and Obesity
Program in Developmental Endocrinology and Genetics
(PDEGEN)
Eunice Kennedy Shriver National Institute of Child
Health and Human Development (NICHD), NIH
Bethesda, Maryland

Jeanmarie Perrone, M.D., FACMT

Associate Professor, Emergency Medicine
Director, Division of Medical Toxicology
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania

FDA PARTICIPANTS (Non-Voting)

Curtis J. Rosebraugh, M.D., M.P.H.

Director
Office of Drug Evaluation II (ODE-II)
Office of New Drugs (OND), CDER, FDA

Eric C. Colman, M.D.

Deputy Director
Division of Metabolism and Endocrinology Products
(DMEP), ODE-II, OND, CDER, FDA

Todd Bourcier, Ph.D.

Supervisory Pharmacologist
DMEP, ODE-II, OND, CDER, FDA

Julie Golden, M.D.

Medical Reviewer
DMEP, ODE-II, OND, CDER, FDA

Fred Alavi, Ph.D.

Pharmacologist
DMEP, ODE-II, OND, CDER, FDA